From Nasdaq.: 2025-06-02 21:40:00

Genentech reported positive Phase III results for Tecentriq in combination with lurbinectedin as first-line maintenance treatment for ES-SCLC. The combination reduced risk of disease progression or death by 46% and risk of death by 27%. Median OS was 13.2 months with the combination versus 10.6 months with Tecentriq alone. Median PFS was 5.4 months versus 2.1 months. Safety profiles were consistent with known data. The trial was sponsored by Genentech and co-funded by Jazz Pharmaceuticals. No new safety signals were observed. More health news available on rttnews.com.



Read more at Nasdaq.: Genentech’s Tecentriq & Lurbinectedin Show Positive Results In Phase III Trial For ES-SCLC